Overview
The OVA-HiLyte™ Fluor 488 Conjugate is a powerful fluorescent dye-conjugated ovalbumin (OVA) that offers significant utility in a variety of biological studies. With a molecular mass of 42.7 kDa, ovalbumin is commonly used as a protein mass standard, making this conjugate ideal for applications that require precision in molecular weight. Its bright fluorescence allows for effective tracking in assays related to antigen uptake, lymphatic circulation, and drug delivery. By integrating the OVA-HiLyte™ Fluor 488 Conjugate into your research, you can enhance the clarity and accuracy of your experiments.
Key Features
- Fluorescent dye conjugate for tracking antigens
- Excitation/Emission wavelength: 499 nm/523 nm
- Excellent for lymphatic circulation studies and drug delivery research
- Reliable protein mass standard
- Simple to use and integrate into existing assays
Specifications
| Product Name | OVA-HiLyte™ Fluor 488 Conjugate |
| Type | Labeled Protein |
| Molecular Weight | 42.7 kDa |
| Package Size | 1 mg |
| Fluorescence | 499 nm/523 nm |
FAQ
What are the primary applications of OVA-HiLyte™ Fluor 488 Conjugate?
This conjugate is primarily used in antigen uptake assays, lymphatic circulation tracking, and drug delivery studies, making it versatile for various experimental designs.
How does the fluorescence intensity of the OVA-HiLyte™ Fluor 488 Conjugate perform in assays?
The conjugate exhibits optimal fluorescence at its specific excitation and emission wavelengths, allowing for clear visualization and tracking of biological processes in real-time.
Can I use OVA-HiLyte™ Fluor 488 Conjugate with other OVA conjugates?
Yes, combining it with other conjugates, such as the OVA-HiLyte™ Fluor 647 Conjugate or OVA-HiLyte™ Fluor 555 Conjugatecan enhance your experimental outcomes by providing multi-channel analysis capabilities.
Get your OVA-HiLyte™ Fluor 488 Conjugate today and optimize your research with reliable fluorescent labeling!
Related Products
Browse more in Labeled proteins.



Reviews
There are no reviews yet.